Abstract:Highlights • S. aureus exists in the synovial fluid of patients in the form of a "Trojan horse", avoiding antibiotic treatment and mediating infection recurrence. • The main host cell types of MRSA in implant infection in mice are macrophages, osteoclasts, synoviocytes and osteoblasts. • The modified SpA antibody (M0662) from a clinical strain has a high affinity with SpA surface antigen of S. aureus (KD<10 -3 nM). • AAC captures extracellular S. aureus and acts as a "biological bomb" to rapidly eliminate S. aureus in the cell. • Application of AACs in the implant infection model significantly improved the bactericidal effect of vancomycin and blocked bacterial biofilm formation. Introduction Treating orthopedic implant-associated infections, especially those caused by Staphylococcus aureus (S. aureus) , remains a significant challenge. S. aureus has the ability to invade host cells, enabling it to evade both antibiotics and immune responses during infection, which may result in clinical treatment failures. Therefore, it is critical to identify the host cell type of implant-associated intracellular S. aureus infections and to develop a strategy for highly targeted delivery of antibiotics to the host cells. Objectives Introduced an antibody-antibiotic conjugate (AAC) for the targeted elimination of intracellular S. aureus . Methods The AAC comprises of a human monoclonal antibody (M0662) directly recognizes the surface antigen of S. aureus , Staphylococcus protein A, which is conjugated with vancomycin through cathepsin-sensitive linkers that are cleavable in the proteolytic environment of the intracellular phagolysosome. AAC, vancomycin and vancomycin combined with AAC were used in vitro intracellular infection and mice implant infection models. We then tested the effect of AAC in vivo and in vivo by fluorescence imaging, in vivo imaging, bacterial quantitative analysis and bacterial biofilm imaging. Results In vitro, it was observed that AAC captured extracellular S. aureus and co-entered the cells, and subsequently released vancomycin to induce rapid elimination of intracellular S. aureus . In the implant infection model, AAC significantly improved the bactericidal effect of vancomycin. Scanning electron microscopy showed that the application of AAC effectively blocked the formation of bacterial biofilm. Further histochemical and micro-CT analysis showed AAC significantly reduced the level of bone marrow density (BMD) and bone volume fraction (BV/TV) reduction caused by bacterial infection in the distal femur of mice compared to vancomycin treatment alone. Conclusions The application of AAC in an implant infection model showed that it significantly improved the bactericidal effects of vancomycin and effectively blocked the formation of bacterial biofilms, without apparent toxicity to the host. Graphical abstract Scheme illustration of Antibody-antibiotic conjugates (AAC) target S. aureus and mediate endocytosis to kill bacteria after entry into the cell. The proposed mechanism suggests that S. aureus-AAC complex mediates endocytosis through the antibody Fcγ receptor, and cathepsin cleaves the intracellular AAC-linker to release vancomycin. Subsequently, vancomycin completed the elimination of S. aureus in the cell. Download : Download high-res image (182KB) Download : Download full-size image

Novel antibody-antibiotic conjugate eliminates intracellular S. aureus

Novel antibody-antibiotic conjugate using KRM-1657 as payload eliminates intracellular MRSA in vitro and in vivo

Antibody-antibiotic conjugate targeted therapy for orthopedic implant-associated intracellular S. aureus infections

Targeting Hidden Pathogens: Cell-Penetrating Enzybiotics Eradicate Intracellular Drug-Resistant Staphylococcus aureus

Bacteria targeting nanoparticles with microenvironment responsive antibiotic release to eliminate intracellular S. aureus and associated infection.

Comparative in vitro efficacy of antibiotics against the intracellular reservoir of Staphylococcus aureus

Sustained Activity Of Novel Thiomab Antibody-Antibiotic Conjugate Against Staphylococcus Aureus In A Mouse Model: Longitudinal Pharmacodynamic Assessment By Bioluminescence Imaging

Overcoming Planktonic and Intracellular Staphylococcus Aureus-Associated Infection with a Cell-Penetrating Peptide-Conjugated Antimicrobial Peptide

Potential Therapeutic Targets for Combination Antibody Therapy Against Staphylococcus aureus Infections

Multivalent human antibody-centyrin fusion protein to prevent and treat Staphylococcus aureus infections

Identifying Potential Therapeutic Targets of Methicillin-resistant Staphylococcus Aureus Through in Vivo Proteomic Analysis

Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus Disease

Triple-acting Lytic Enzyme Treatment of Drug-Resistant and Intracellular Staphylococcus aureus

Clearance of Staphylococcus aureus from In Vivo Models of Chronic Infection by Immunization Requires Both Planktonic and Biofilm Antigens

Novel human monoclonal antibodies targeting the F subunit of leukocidins reduce disease progression and mortality caused by Staphylococcus aureus

Mechanism of Action for an All-in-One Monoclonal Antibody Against Staphylococcus Aureus Infection.

Isolation and characterization of a multidrug-resistant Staphylococcus aureus infecting phage and its therapeutic use in mice

Intracellular Habitation of Staphylococcus aureus: Molecular Mechanisms and Prospects for Antimicrobial Therapy

A high-throughput cytotoxicity screening platform reveals agr-independent mutations in bacteraemia-associated Staphylococcus aureus that promote intracellular persistence

Bactericidal fully human single‐chain fragment variable antibodies protect mice against methicillin‐resistant Staphylococcus aureus bacteraemia

Antibiotic-loaded Nanoparticles Targeted to the Site of Infection Enhance Antibacterial Efficacy